



**CM HOSPITALAR S.A.**

Publicly Traded Company

Corporate Taxpayer's ID (CNPJ/MF) 12.420.164/0001-57

Company's Registry (NIRE) 35.300.486.854

CVM Code 25682

ISIN: BRVVEOACNOR0

B3 Ticker: VVEO3

**NOTICE TO THE MARKET**

**Acquisition of 100% of Far.me**

**CM Hospitalar S.A.** (**'Viveo'** or **'Company'**), an ecosystem of companies specialized in each link of the healthcare chain, in compliance with Article 157, §4, of the Brazilian Corporate Law (Law 6404 of 1976) and Article 2 of CVM Resolution 44 of 2021, informs that, on February 03<sup>rd</sup>, 2023, Viveo has signed a share purchase agreement (**'the Agreement'**), for completion of acquisition of the entire share capital of Far.me Farmacoterapia Otimizada S.A. (**'Far.me'**).

Far.me, operating in Greater São Paulo and in Belo Horizonte, is a pharmaceuticals provider specializing in offering personalized and digital care service by monthly subscription for delivery of medications, segregated by date and time of day, in accordance with the patient's medical prescription. The solution is associated with pharmaceutical monitoring by a healthcare team which uses technology to support patients and healthcare institutions over the whole chain of provision, from collection and analysis of the medical prescription, and coordination of care with the clinical team to mitigate risks to health, to actions to increase levels of adhesion to treatment protocols and the patient's well-being.

This integrated end-to-end service ensures improved safety and efficiency over the whole healthcare provision process, from execution of the initial purchase to delivery in the healthcare institution or to the patient's home. Far.me primarily serves patients with chronic conditions, who have needs for recurring supply and use of medication.

Viveo made its first investment in Far.me in 2020. Its acquisition of 100% of the shares in the company, together with its acquisition of Boxifarma, in 2022, will enable Viveo to strengthen and enhance its strategy and activity in the Direct to Patient market segment. To further develop these services, optimize service levels of last-mile logistics, and make its express delivery of healthcare products even more robust and convenient, Viveo has also made a minority investment in the healthtech company X Farmácia.

To manage Far.me, jointly with Boxifarma (**'the Companies'**), Viveo has contracted Rafael Mandelbaum as CEO. He will report to Leonardo Byrro, CEO of Viveo. Rafael has Israeli and Brazilian citizenship, has worked in Brazil for more than 10 years, and has wide experience in startups. After working at QuintoAndar, he was Vice-President for Operations at Loggi. The founders of the Companies will continue to participate in building the businesses, for an indeterminate period.

For the acquisition of the remaining equity interest in Far.Me, the Company paid in loans carried out in 2021 and 2022 with an updated amount of approximately R\$20.6 million and will pay an additional amount of R\$4.0 million, of which R\$2.7 million was paid on February 6, 2022. Far.Me's revenue in 2022 was approximately R\$8.0 million.

All conditions precedent were fulfilled for the signature and the closing of the acquisition of Far.me took place on February 3<sup>rd</sup>, 2023.

Ribeirão Preto, February 7<sup>th</sup>, 2023  
**Flávia Carvalho**  
**Investor Relations and M&A Officer**  
**CM Hospitalar S.A.**